Reply: Automation and Artificial Intelligence Are the Strategic Keys for an Effective Defense Against Growing Threats in the Digital World
Today, cybersecurity represents an essential priority in the implementation of new technologies, especially given the crucial role that they have come to play in our private and professional lives. Smart Homes, Connected Cars, Delivery Robots: this evolution will not stop and so, in tandem, it will be necessary to develop automated and AI-based solutions to combat the growing number of security threats. The risks from these attacks are attributable to several factors, such as increasingly complex and widespread digital networks and a growing sensitivity to data privacy issues. These are the themes that emerge from the new “ Cybersecurity Automation ” research conducted by Reply, thanks to the proprietary SONAR platform and the support of PAC (Teknowlogy Group) in measuring the markets and projecting their growth.
In particular, the research estimates the principal market trends in security system automation, based on analysis of studies of the sector combined with evidence from Reply’s own customers. The data compares two different clusters of countries: the “Europe-5” (Italy, Germany, France, the Netherlands, Belgium) and the “Big-5” (USA, UK, Brazil, China, India) in order to understand how new AI solutions are implemented in the constantly evolving landscape of cybersecurity.
As cyberattacks like hacking, phishing, ransomware and malware have become more frequent and sophisticated, resulting in trillions of euros in damages for businesses both in terms of profit and brand reputation, the adoption of hyperautomation techniques has demonstrated how artificial intelligence and machine learning represent possible solutions. Furthermore, these technologies will need to be applied at every stage of protection, from software to infrastructure, and from devices to cloud computing.
Of the 300 billion in investments that the global cybersecurity market will make in the next five years, a large part will be directed toward automating security measures in order to improve detection and response times to threats in four different segments: Application security, Endpoint security, Data security and protection, Internet of Things security.
Application Security. Developers who first introduced the concept of “security by design,” an adaptive approach to technology design security, are now focusing on an even closer collaboration with the operations and security teams, termed DevSecOps. This newer model emphasizes the integration of security measures throughout the entire application development lifecycle. Automating testing at every step is crucial for decreasing the number of vulnerabilities in an application, and many testing and analysis tools are further integrating AI to increase their accuracy or capabilities. Investments in application security automation in the Europe-5 market are expected to see enormous growth, around seven times the current value, reaching 669 million euros by 2026. A similar growth is forecast in the Big-5 market, with investments rising to 3.5 billion euros.
Endpoint security. Endpoints, such as desktops, laptops, smartphones and servers, are sensitive elements and therefore possible sources of entry for cyberattacks if not adequately protected. In recent years, the average number of endpoints within a company has significantly increased, so identifying and adopting efficient and comprehensive protection tools is essential for survival. Endpoint detection and response (EDR) and Extended detection and response (XDR) are both tools created to accelerate the response time to emerging security threats, delegating repetitive and monotonous tasks to software that can manage them more efficiently. Investments in these tools are expected to increase in both the Europe-5 and Big-5 markets over the next few years, reaching 757 million euros and 3.65 billion euros respectively. There are also a multitude of other tools and systems dedicated to incident management that can be integrated at the enterprise level. For example, in Security Orchestration Automation and Response (SOAR) solutions, AI can be introduced in key areas such as threat management or incident response.
Data security and protection. Data security threats, also called data breaches, can cause significant damage to a business, resulting in risky legal complications or devaluating brand reputation. Ensuring that data is well-preserved and well-stored is an increasingly important challenge. It is easy to imagine how many different security threats can come from poor data manipulation, cyberattacks, untrustworthy employees, or even just from inexperienced technology users. Artificial intelligence is a tool for simplifying these data security procedures, from discovery to classification to remediation. Security automation is expected to reduce the cost of a data breach by playing an important role in various phases of a cyberattack, such as in data loss prevention tools (DLP), encryption, and tokenization. In an effort to better protect system security and data privacy, companies in the Europe-5 cluster are expected to invest 915 million euros in data security automation by 2026. The Big-5 market will quadruple its value, reaching 4.4 billion euros in the same timeframe.
Internet of Things security. The interconnected nature of IoT allows for every device in a network to be a potential weak point, meaning even a single vulnerability could be enough to shut down an entire infrastructure. By 2026, it is estimated that there will be 80 billion IoT devices on earth. The impressive range of abilities offered by IoT devices for different industries, though enabling smart factories, smart logistics, or smart speakers, prevents the creation of a standardized solution for IoT cybersecurity. As IoT networks reach fields ranging from healthcare to automotive, the risks only multiply. Therefore, IoT security is one of the most difficult challenges: the boundary between IT and OT (Operational Technology) must be overcome in order for IoT to unleash its full business value. As such, it is estimated that the IoT security automation market will exceed the 1-billion-euro mark in the Europe-5 cluster by 2026. In the Big-5 market, investments will reach a whopping 4.6 billion euros.
Filippo Rizzante, Reply’s CTO, has stated: “The significant growth that we are witnessing in the cybersecurity sector is not driven by trend, but by necessity. Every day, cyberattacks hit public and private services, government and healthcare systems, causing enormous damage and costs; therefore, it is more urgent than ever to reconsider security strategies and reach new levels of maturity through automation, remembering that though artificial intelligence has increased the threat of the hacker, it is through taking advantage of AI’s opportunities that cyberattacks can be prevented and countered.”
The complete research is downloadable here. This new research is part of the Reply Market Research series, which includes the reports “From Cloud to Edge”, “Industrial IoT: a reality check” and “Hybrid Work.”
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] is specialized in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly focused companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005087/en/
Contact information
Press contacts
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Aaron Miani
a.miani@reply.com
Tel. +44 (0)20 7730 6000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom